GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bright Minds Biosciences Inc (NAS:DRUG) » Definitions » Cash Ratio

Bright Minds Biosciences (Bright Minds Biosciences) Cash Ratio : 7.91 (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Bright Minds Biosciences Cash Ratio?

The Cash Ratio measures a company’s ability to meet its short-term obligations with cash and near-cash resources. It is calculated as a company's Cash, Cash Equivalents, Marketable Securities divides by its Total Current Liabilities. Bright Minds Biosciences's Cash Ratio for the quarter that ended in Dec. 2023 was 7.91.

Bright Minds Biosciences has a Cash Ratio of 7.91. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.

The historical rank and industry rank for Bright Minds Biosciences's Cash Ratio or its related term are showing as below:

DRUG' s Cash Ratio Range Over the Past 10 Years
Min: 5.3   Med: 21.49   Max: 68.13
Current: 7.92

During the past 4 years, Bright Minds Biosciences's highest Cash Ratio was 68.13. The lowest was 5.30. And the median was 21.49.

DRUG's Cash Ratio is ranked better than
78.25% of 1522 companies
in the Biotechnology industry
Industry Median: 2.93 vs DRUG: 7.92

Bright Minds Biosciences Cash Ratio Historical Data

The historical data trend for Bright Minds Biosciences's Cash Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bright Minds Biosciences Cash Ratio Chart

Bright Minds Biosciences Annual Data
Trend Sep20 Sep21 Sep22 Sep23
Cash Ratio
5.31 30.94 7.90 23.98

Bright Minds Biosciences Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cash Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 21.22 9.62 11.27 23.98 7.91

Competitive Comparison of Bright Minds Biosciences's Cash Ratio

For the Biotechnology subindustry, Bright Minds Biosciences's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bright Minds Biosciences's Cash Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Bright Minds Biosciences's Cash Ratio distribution charts can be found below:

* The bar in red indicates where Bright Minds Biosciences's Cash Ratio falls into.



Bright Minds Biosciences Cash Ratio Calculation

The Cash Ratio measures a company's ability to meet its short-term obligations with its cash and near-cash resources.

Bright Minds Biosciences's Cash Ratio for the fiscal year that ended in Sep. 2023 is calculated as:

Cash Ratio (A: Sep. 2023 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=4.987/0.208
=23.98

Bright Minds Biosciences's Cash Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash Ratio (Q: Dec. 2023 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=5.04/0.637
=7.91

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Bright Minds Biosciences  (NAS:DRUG) Cash Ratio Explanation

The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.

The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.

In general, the higher the cash ratio, the better the company's liquidity position.


Bright Minds Biosciences Cash Ratio Related Terms

Thank you for viewing the detailed overview of Bright Minds Biosciences's Cash Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Bright Minds Biosciences (Bright Minds Biosciences) Business Description

Traded in Other Exchanges
Address
19 Vestry Street, New York, NY, USA, 10013
Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.